My guess is that Revance has gone through the transition from being an emerging biotech with a price based upon wishes dreams, and High Hopes to being an established biotech, whose price is based upon actual earnings and ROI.
The CD stream will not begin before next year. And with what the market has learned about the aesthetic stream, that’s going to be a very slow build up.
Market Data 
Markets 
AI
